Details of Disease

General Information of Disease (ID: DISHL4NT)

Disease Name Chronic hepatitis B virus infection
Synonyms hepatitis B, chronic; chronic Hepatitis B; hepatitis B infection, chronic
Definition Chronic form of hepatitis B infection.
Disease Hierarchy
DISLQ2XY: Hepatitis B virus infection
DISHL4NT: Chronic hepatitis B virus infection
Disease Identifiers
MONDO ID
MONDO_0005366
MESH ID
D019694
UMLS CUI
C0524909
MedGen ID
99834
SNOMED CT ID
61977001

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)
This Disease is Treated as An Indication in 3 Approved Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
Lamivudine DMI347A Approved Small molecular drug [1]
Peginterferon alfa-2a DMJI3BA Approved NA [2]
Tenofovir DM1IS6U Approved Small molecular drug [3]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)
This Disease Is Related to 47 DTT Molecule(s)
Gene Name DTT ID Evidence Level Mode of Inheritance REF
BTLA TTER58P Limited Genetic Variation [4]
CD209 TTBXIM9 Limited Biomarker [5]
CXCL10 TTQOVYA Limited Altered Expression [6]
CYP21A2 TTP4GLG Limited Genetic Variation [7]
HP TTLC8E1 Limited Altered Expression [8]
IFNA2 TTSIUJ9 Limited Biomarker [9]
IFNAR1 TTSYFMA Limited Posttranslational Modification [10]
IL10RB TTJTRMK Limited Biomarker [11]
ITGAE TTH0Z37 Limited Altered Expression [12]
KLRG1 TT299E6 Limited Biomarker [13]
LIPA TTS8T1M Limited Genetic Variation [14]
LTBR TTFO0PM Limited Genetic Variation [15]
NOTCH4 TTXDIK2 Limited Genetic Variation [7]
PDCD1 TTNBFWK Limited Posttranslational Modification [16]
SLC10A1 TTWZRY5 Limited Genetic Variation [17]
TM6SF2 TTE1OHM Limited Genetic Variation [18]
CD40 TT1ERKL Disputed Genetic Variation [7]
EHMT2 TTS6RZT Disputed Genetic Variation [19]
APOBEC3G TTP96KH moderate Altered Expression [20]
FGL2 TTYBS89 moderate Altered Expression [21]
FZD7 TTUQMO5 moderate Altered Expression [22]
KIR2DL1 TT4UXPE moderate Biomarker [23]
NNT TTKIH76 moderate Biomarker [24]
AFP TTCFEA1 Strong Biomarker [25]
BGN TT0JPVF Strong Biomarker [26]
CCN2 TTIL516 Strong Biomarker [27]
CD14 TT6I7DC Strong Biomarker [28]
CD69 TTPQE9F Strong Altered Expression [29]
CFB TTA0P7K Strong Genetic Variation [7]
CXCR5 TTIW59R Strong Genetic Variation [30]
DDX58 TTVB0O3 Strong Altered Expression [31]
FCGR3A TTIFOC0 Strong Biomarker [32]
GGT1 TTZVT7O Strong Biomarker [33]
HLA-DQB2 TTL7VOU Strong Genetic Variation [34]
IFNAR2 TTMQB37 Strong Genetic Variation [35]
IL21 TT9QEJ6 Strong Genetic Variation [36]
IL21R TTZO9B0 Strong Genetic Variation [36]
IL23A TTC1GLB Strong Biomarker [37]
KIR2DL3 TTEX3SI Strong Genetic Variation [38]
KLRC1 TTC4IMS Strong Altered Expression [39]
LAG3 TTNVXAW Strong Altered Expression [40]
PINX1 TT4FJ3A Strong Biomarker [41]
PNPLA3 TTEUAEH Strong Genetic Variation [42]
SLC17A5 TTFSUIA Strong Biomarker [33]
TEP1 TTQGAVX Strong Genetic Variation [41]
TLR3 TTD24Y0 Strong Genetic Variation [43]
TLR7 TTRJ1K4 Strong Biomarker [44]
------------------------------------------------------------------------------------
⏷ Show the Full List of 47 DTT(s)
This Disease Is Related to 4 DTP Molecule(s)
Gene Name DTP ID Evidence Level Mode of Inheritance REF
SLC28A1 DT0EQPW Limited Genetic Variation [45]
ABCC6 DT582KR moderate Altered Expression [46]
SLC26A5 DTPGHJ7 Strong Genetic Variation [47]
SLC4A1 DTB0Q3P Strong Genetic Variation [48]
------------------------------------------------------------------------------------
This Disease Is Related to 4 DME Molecule(s)
Gene Name DME ID Evidence Level Mode of Inheritance REF
CMPK1 DEMPH4I Limited Biomarker [49]
UGT1A7 DEZO4N3 moderate Biomarker [50]
ACP5 DESITDW Strong Biomarker [51]
UGT2B28 DEB7I4M Strong Genetic Variation [52]
------------------------------------------------------------------------------------
This Disease Is Related to 74 DOT Molecule(s)
Gene Name DOT ID Evidence Level Mode of Inheritance REF
AGO1 OTD3R434 Limited Genetic Variation [53]
APOA5 OTEVKLVA Limited Biomarker [54]
ASCC3 OTF6DCYB Limited Genetic Variation [55]
BATF OT9VSD2D Limited Altered Expression [56]
C2 OTHMF4YM Limited Genetic Variation [57]
COL22A1 OTSWGZRD Limited Genetic Variation [58]
CXCL6 OTFTCQ4O Limited Altered Expression [59]
DSTN OTMXO4YB Limited Biomarker [60]
HAVCR2 OTOL603T Limited Biomarker [61]
HLA-DPA1 OT7OG7Y2 Limited Genetic Variation [7]
IFNA1 OTPMKY0L Limited Biomarker [58]
JMJD6 OTILR7E4 Limited Altered Expression [62]
KCTD9 OTBN6ZUC Limited Biomarker [63]
MAP6 OTPUI00F Limited Biomarker [64]
MAVS OTTQ0J64 Limited Altered Expression [65]
MOV10 OT0KAY9G Limited Altered Expression [66]
MYOM2 OTD2UOXW Limited Biomarker [67]
NBAS OTW9IBRI Limited Genetic Variation [68]
NMI OTYVG3NM Limited Biomarker [69]
PAEP OTQA0NV4 Limited Biomarker [70]
PCOLCE OTJXOAN4 Limited Altered Expression [71]
POLR3G OTU3TGQ9 Limited Genetic Variation [68]
PPIP5K1 OT06HYH8 Limited Altered Expression [65]
RGN OTD04KB1 Limited Biomarker [72]
SFTA2 OTVRIUIV Limited Genetic Variation [73]
SFXN1 OTL66767 Limited Genetic Variation [74]
SIGLEC9 OTZC7SIM Limited Biomarker [75]
STAT4 OTAK3VFR Limited Genetic Variation [76]
TNIP1 OTRAOTEW Limited Genetic Variation [77]
C9 OT7I5FDX moderate Genetic Variation [78]
CIITA OTRJNZFO moderate Genetic Variation [79]
IBSP OT29944Y moderate Genetic Variation [80]
KLRC4 OTXOSGIB moderate Genetic Variation [81]
KLRD1 OTMYLOV4 moderate Genetic Variation [81]
MARCHF8 OTH7PNN2 moderate Genetic Variation [82]
MLXIP OT30UNI7 moderate Genetic Variation [82]
MYLIP OTL0PFGV moderate Genetic Variation [82]
PAK3 OT80M3BV moderate Altered Expression [46]
RCOR3 OT5LATME moderate Altered Expression [83]
SP2 OT1YI07B moderate Genetic Variation [80]
SPATA1 OTFZ5T2E moderate Genetic Variation [80]
TRAPPC1 OTSASU6U moderate Biomarker [84]
ADAR OTQNOHR8 Strong Altered Expression [85]
AIM2 OT86QUI8 Strong Altered Expression [86]
ARC OTN2QQPG Strong Biomarker [87]
CDO1 OTLG1P77 Strong Posttranslational Modification [88]
CLTC OTBFASMA Strong Genetic Variation [48]
EIF3A OTFABY9G Strong Altered Expression [89]
EIF3B OTF67VPH Strong Altered Expression [89]
EIF3J OTJ4TAWK Strong Biomarker [89]
EIF4B OTE8TXA8 Strong Altered Expression [89]
EIF5 OT79PQUN Strong Altered Expression [89]
EIF6 OTEXMUED Strong Altered Expression [89]
EP400 OTVQ75NX Strong Genetic Variation [90]
FCER1A OTIRUOHF Strong Genetic Variation [68]
FCGR3B OTSLSPZG Strong Biomarker [32]
GGTLC1 OTWJKUHQ Strong Biomarker [91]
GOLM1 OTOZSV6O Strong Biomarker [33]
GPT2 OTS5VF7N Strong Biomarker [92]
GSTM3 OTLA2WJT Strong Posttranslational Modification [93]
HLA-C OTV38BUJ Strong Genetic Variation [94]
HLA-DOA OTZE5Q7R Strong Genetic Variation [7]
HLA-DPB1 OTW8JHU2 Strong Genetic Variation [95]
HSPA1L OTC2V1K6 Strong Genetic Variation [96]
IFI16 OT4SPU0U Strong Biomarker [86]
IFNGR1 OTCTQBWW Strong Genetic Variation [97]
ISG20 OTCWRJJW Strong Biomarker [98]
LGALS3BP OT9AGQKH Strong Biomarker [99]
LGALS9 OT7MF91K Strong Biomarker [100]
PLAAT4 OTI66SAJ Strong Altered Expression [31]
RBM45 OTWTHD77 Strong Genetic Variation [101]
ROBO3 OTPVG40S Strong Altered Expression [31]
TCF19 OT7NKLF9 Strong Genetic Variation [7]
TNFAIP8L2 OTII0RM0 Strong Biomarker [102]
------------------------------------------------------------------------------------
⏷ Show the Full List of 74 DOT(s)

References

1 Lamivudine FDA Label
2 Entecavir and Peginterferon Alfa-2a in Adults With Hepatitis B e Antigen-Positive Immune-Tolerant Chronic Hepatitis B Virus Infection. Hepatology. 2019 Jun;69(6):2338-2348.
3 Tenofovir FDA Label
4 The Influence of B and T Lymphocyte Attenuator Genetic Variants on Susceptibility to Chronic Hepatitis B Virus Infection.Cell Physiol Biochem. 2018;45(6):2540-2547. doi: 10.1159/000488272. Epub 2018 Mar 16.
5 Common polymorphic effectors of immunity against hepatitis B and C modulate susceptibility to infection and spontaneous clearance in a Moroccan population.Infect Genet Evol. 2014 Aug;26:1-7. doi: 10.1016/j.meegid.2014.04.019. Epub 2014 May 4.
6 Circulating BAFF and CXCL10 levels predict response to pegylated interferon in patients with HBeAg-positive chronic hepatitis B.Asian Pac J Allergy Immunol. 2021 Jun;39(2):129-135. doi: 10.12932/AP-050718-0365.
7 Genetic variants in five novel loci including CFB and CD40 predispose to chronic hepatitis B.Hepatology. 2015 Jul;62(1):118-28. doi: 10.1002/hep.27794. Epub 2015 Apr 28.
8 Serum Zonulin in HBV-Associated Chronic Hepatitis, Liver Cirrhosis, and Hepatocellular Carcinoma.Dis Markers. 2019 Aug 14;2019:5945721. doi: 10.1155/2019/5945721. eCollection 2019.
9 Efficacy and safety of interferon alpha-2b versus pegylated interferon alpha-2a monotherapy in children with chronic hepatitis B: a real-life cohort study from Shanghai, China.World J Pediatr. 2019 Dec;15(6):595-600. doi: 10.1007/s12519-019-00303-w. Epub 2019 Sep 5.
10 Decreased Methylation of IFNAR Gene Promoter from Peripheral Blood Mononuclear Cells Is Associated with Oxidative Stress in Chronic Hepatitis B.J Interferon Cytokine Res. 2018 Nov;38(11):480-490. doi: 10.1089/jir.2018.0068. Epub 2018 Oct 31.
11 Association of IFNAR2 and IL10RB genes in chronic hepatitis B virus infection.Tissue Antigens. 2013 Jul;82(1):21-5. doi: 10.1111/tan.12133.
12 Human intrahepatic CD69?CD8+ T cells have a tissue resident memory T cell phenotype with reduced cytolytic capacity.Sci Rep. 2017 Jul 21;7(1):6172. doi: 10.1038/s41598-017-06352-3.
13 KLRG1+ natural killer cells exert a novel antifibrotic function in chronic hepatitis B.J Hepatol. 2019 Aug;71(2):252-264. doi: 10.1016/j.jhep.2019.03.012. Epub 2019 Mar 21.
14 Comparison of INNO-LIPA and TRUGENE assays for genotyping and drug-resistance mutations in chronic hepatitis B virus infection.Intervirology. 2013;56(3):190-4. doi: 10.1159/000348502. Epub 2013 Apr 17.
15 Association of LTBR polymorphisms with chronic hepatitis B virus infection and hepatitis B virus-related hepatocellular carcinoma.Int Immunopharmacol. 2017 Aug;49:126-131. doi: 10.1016/j.intimp.2017.05.031. Epub 2017 May 30.
16 Correlation of CpG methylation of the Pdcd1 gene with PD-1 expression on CD8(+) T cells and medical laboratory indicators in chronic hepatitis B infection.J Gene Med. 2020 Feb;22(2):e3148. doi: 10.1002/jgm.3148. Epub 2020 Jan 9.
17 Association of the S267F variant on NTCP gene and treatment response to pegylated interferon in patients with chronic hepatitis B: a multicentre study.Antivir Ther. 2018;23(1):67-75. doi: 10.3851/IMP3179.
18 Diverse impacts of the rs58542926 E167K variant in TM6SF2 on viral and metabolic liver disease phenotypes.Hepatology. 2016 Jul;64(1):34-46. doi: 10.1002/hep.28475. Epub 2016 Mar 30.
19 Identification of additional EHMT2 variant associated with the risk of chronic hepatitis B by GWAS follow-up study.Genes Immun. 2019 Jan;20(1):1-9. doi: 10.1038/s41435-017-0004-x. Epub 2017 Dec 14.
20 Interferon-alpha induces high expression of APOBEC3G and STAT-1 in vitro and in vivo.Int J Mol Sci. 2010 Sep 20;11(9):3501-12. doi: 10.3390/ijms11093501.
21 The Fgl2/fibroleukin prothrombinase contributes to immunologically mediated thrombosis in experimental and human viral hepatitis.J Clin Invest. 2003 Jul;112(1):58-66. doi: 10.1172/JCI18114.
22 Functional consequences of frizzled-7 receptor overexpression in human hepatocellular carcinoma.Gastroenterology. 2004 Oct;127(4):1110-22. doi: 10.1053/j.gastro.2004.07.009.
23 Inhibitory KIR and specific HLA-C gene combinations confer susceptibility to or protection against chronic hepatitis B.Clin Immunol. 2010 Oct;137(1):139-46. doi: 10.1016/j.clim.2010.05.011.
24 Treatment options in HBV.J Hepatol. 2006;44(1 Suppl):S77-83. doi: 10.1016/j.jhep.2005.11.018. Epub 2005 Nov 28.
25 Diagnostic value of gamma-glutamyltransferase/aspartate aminotransferase ratio, protein induced by vitamin K absence or antagonist II, and alpha-fetoprotein in hepatitis B virus-related hepatocellular carcinoma.World J Gastroenterol. 2019 Sep 28;25(36):5515-5529. doi: 10.3748/wjg.v25.i36.5515.
26 Significance of biglycan and osteopontin as non-invasive markers of liver fibrosis in patients with chronic hepatitis B virus and chronic hepatitis C virus.J Investig Med. 2019 Mar;67(3):681-685. doi: 10.1136/jim-2018-000840. Epub 2018 Oct 31.
27 Expression of heat shock protein 47, transforming growth factor-beta 1, and connective tissue growth factor in liver tissue of patients with Schistosoma japonicum-induced hepatic fibrosis.Parasitology. 2015 Feb;142(2):341-51. doi: 10.1017/S0031182014001115. Epub 2014 Aug 11.
28 CD137-mediated pathogenesis from chronic hepatitis to hepatocellular carcinoma in hepatitis B virus-transgenic mice.J Immunol. 2010 Dec 15;185(12):7654-62. doi: 10.4049/jimmunol.1000927. Epub 2010 Nov 8.
29 Decrease of CD69 levels on TCR V7.2(+)CD4(+) innate-like lymphocytes is associated with impaired cytotoxic functions in chronic hepatitis B virus-infected patients.Innate Immun. 2017 Jul;23(5):459-467. doi: 10.1177/1753425917714854. Epub 2017 Jun 13.
30 Genetic variations in the CXCR5 gene decrease the risk of clinical relapse after discontinuation of nucleos(t)ide analogue therapy in patients with chronic hepatitis B.Infect Genet Evol. 2020 Mar;78:104124. doi: 10.1016/j.meegid.2019.104124. Epub 2019 Nov 22.
31 Toll-like receptors, long non-coding RNA NEAT1, and RIG-I expression are associated with HBeAg-positive chronic hepatitis B patients in the active phase.J Clin Lab Anal. 2019 Jun;33(5):e22886. doi: 10.1002/jcla.22886. Epub 2019 Mar 29.
32 NK-cell responses are biased towards CD16-mediated effector functions in chronic hepatitis B virus infection.J Hepatol. 2019 Mar;70(3):351-360. doi: 10.1016/j.jhep.2018.10.006. Epub 2018 Oct 18.
33 Serum GP73 combined AST and GGT reflects moderate to severe liver inflammation in chronic hepatitis B.Clin Chim Acta. 2019 Jun;493:92-97. doi: 10.1016/j.cca.2019.02.019. Epub 2019 Feb 20.
34 Lack of association between human leukocyte antigen polymorphisms rs9277535 and rs7453920 and chronic hepatitis B in a Brazilian population.Genet Mol Res. 2017 May 31;16(2). doi: 10.4238/gmr16029565.
35 HLA-DP and -interferon receptor-2 gene variants and their association with viral hepatitis activity in chronic hepatitis B infection.J Gastroenterol Hepatol. 2014 Mar;29(3):533-9. doi: 10.1111/jgh.12378.
36 Association between Interleukin-21 and Interleukin-21 receptor gene polymorphisms with susceptibility to chronic hepatitis B virus infection and HBV spontaneous clearance in Iranian population.Microb Pathog. 2019 Mar;128:263-267. doi: 10.1016/j.micpath.2019.01.008. Epub 2019 Jan 10.
37 IL-23 production of liver inflammatory macrophages to damaged hepatocytes promotes hepatocellular carcinoma development after chronic hepatitis B virus infection.Biochim Biophys Acta Mol Basis Dis. 2018 Dec;1864(12):3759-3770. doi: 10.1016/j.bbadis.2018.10.004. Epub 2018 Oct 4.
38 The immunoglobulin marker 17 allotype and KIR/HLA genes prevent the development of chronic hepatitis B in humans.Immunology. 2020 Feb;159(2):178-182. doi: 10.1111/imm.13133. Epub 2019 Nov 12.
39 Blocking the natural killer cell inhibitory receptor NKG2A increases activity of human natural killer cells and clears hepatitis B virus infection in mice.Gastroenterology. 2013 Feb;144(2):392-401. doi: 10.1053/j.gastro.2012.10.039. Epub 2012 Oct 26.
40 CD4(+) T cell exhaustion revealed by high PD-1 and LAG-3 expression and the loss of helper T cell function in chronic hepatitis B.BMC Immunol. 2019 Aug 7;20(1):27. doi: 10.1186/s12865-019-0309-9.
41 Association of PINX1 but not TEP1 Polymorphisms with Progression to Hepatocellular Carcinoma in Thai Patients with Chronic Hepatitis B Virus Infection.Asian Pac J Cancer Prev. 2016;17(4):2019-25. doi: 10.7314/apjcp.2016.17.4.2019.
42 The impact of PNPLA3 (rs738409 C>G) polymorphisms on liver histology and long-term clinical outcome in chronic hepatitis B patients.Liver Int. 2015 Feb;35(2):438-47. doi: 10.1111/liv.12695. Epub 2014 Oct 24.
43 Polymorphisms in the Toll-like receptor 3 (TLR3) gene are associated with the natural course of hepatitis B virus infection in Caucasian population.Sci Rep. 2018 Aug 24;8(1):12737. doi: 10.1038/s41598-018-31065-6.
44 Anti-HBV response to toll-like receptor 7 agonist GS-9620 is associated with intrahepatic aggregates of T cells and B cells.J Hepatol. 2018 May;68(5):912-921. doi: 10.1016/j.jhep.2017.12.008. Epub 2017 Dec 14.
45 ABCC4, ABCC5 and SLC28A1 polymorphisms: host genome on responses of chronic hepatitis B patients with entecavir treatment.Antivir Ther. 2016;21(8):689-696. doi: 10.3851/IMP3063. Epub 2016 Jun 29.
46 Differential effect of ARA-AMP on serum DNA polymerase activity and serum HBV-DNA in chronic hepatitis B virus infection. A possible reason for lack of efficacy.J Hepatol. 1986;3 Suppl 2:S81-6. doi: 10.1016/s0168-8278(86)80104-0.
47 Mutations in preS genes of genotype C hepatitis B virus in patients with chronic hepatitis B and hepatocellular carcinoma.J Gastroenterol. 2007 Sep;42(9):761-8. doi: 10.1007/s00535-007-2085-1. Epub 2007 Sep 25.
48 Liver steatosis in children with chronic hepatitis B and C: Prevalence, predictors, and impact on disease progression.Medicine (Baltimore). 2017 Jan;96(3):e5832. doi: 10.1097/MD.0000000000005832.
49 MiR-3613-3p impairs IFN-induced immune response by targeting CMPK1 in chronic hepatitis B.Infect Genet Evol. 2019 Oct;74:103919. doi: 10.1016/j.meegid.2019.103919. Epub 2019 Jun 12.
50 UGT1A7 haplotype is associated with an increased risk of hepatocellular carcinoma in hepatitis B carriers.Cancer Sci. 2008 Feb;99(2):340-4. doi: 10.1111/j.1349-7006.2007.00693.x.
51 Transcriptional profiling on chromosome 19p indicated frequent downregulation of ACP5 expression in hepatocellular carcinoma.Int J Cancer. 2005 May 10;114(6):902-8. doi: 10.1002/ijc.20684.
52 Ages of hepatocellular carcinoma occurrence and life expectancy are associated with a UGT2B28 genomic variation.BMC Cancer. 2019 Dec 5;19(1):1190. doi: 10.1186/s12885-019-6409-3.
53 Association between SNPs in miRNA-machinery genes and chronic hepatitis B in the Chinese Han population.Infect Genet Evol. 2014 Dec;28:113-7. doi: 10.1016/j.meegid.2014.09.015. Epub 2014 Sep 17.
54 Plasma Apolipoprotein A-V Predicts Long-term Survival in Chronic Hepatitis B Patients with Acute-on-Chronic Liver Failure.Sci Rep. 2017 Mar 30;7:45576. doi: 10.1038/srep45576.
55 Correlations between ASCC3 Gene Polymorphisms and Chronic Hepatitis B in a Chinese Han Population.PLoS One. 2015 Nov 4;10(11):e0141861. doi: 10.1371/journal.pone.0141861. eCollection 2015.
56 Increased BATF expression is associated with the severity of liver damage in patients with chronic hepatitis B.Clin Exp Med. 2018 May;18(2):263-272. doi: 10.1007/s10238-017-0480-3. Epub 2017 Nov 21.
57 Genetic association of complement component 2 variants with chronic hepatitis B in a Korean population.Liver Int. 2018 Sep;38(9):1576-1582. doi: 10.1111/liv.13675. Epub 2018 Feb 10.
58 Genome-wide Association Study Identifies Genetic Variants Associated With Early and Sustained Response to (Pegylated) Interferon in Chronic Hepatitis B Patients: The GIANT-B Study.Clin Infect Dis. 2019 Nov 13;69(11):1969-1979. doi: 10.1093/cid/ciz084.
59 CXCL6 promotes human hepatocyte proliferation through the CXCR1-NFB pathway and inhibits collagen I secretion by hepatic stellate cells.Biochem Cell Biol. 2016 Jun;94(3):229-35. doi: 10.1139/bcb-2015-0136. Epub 2016 Jan 28.
60 Tenofovir disoproxil fumarate has a substantial efficacy against multidrug-resistant strains of hepatitis B virus.Liver Int. 2015 Oct;35(10):2265-74. doi: 10.1111/liv.12831. Epub 2015 Apr 17.
61 Tim-3 regulates inflammatory cytokine expression and Th17 cell response induced by monocytes from patients with chronic hepatitis B.Scand J Immunol. 2019 May;89(5):e12755. doi: 10.1111/sji.12755. Epub 2019 Mar 18.
62 Regulation of T cell proliferation by JMJD6 and PDGF-BB during chronic hepatitis B infection.Sci Rep. 2014 Sep 15;4:6359. doi: 10.1038/srep06359.
63 KCTD9 contributes to liver injury through NK cell activation during hepatitis B virus-induced acute-on-chronic liver failure.Clin Immunol. 2013 Mar;146(3):207-16. doi: 10.1016/j.clim.2012.12.013. Epub 2013 Jan 7.
64 Limited sustained response after stopping nucleos(t)ide analogues in patients with chronic hepatitis B: results from a randomised controlled trial (Toronto STOP study).Gut. 2019 Dec;68(12):2206-2213. doi: 10.1136/gutjnl-2019-318981. Epub 2019 Aug 28.
65 Up-regulation of RIP1 and IPS-1 in chronic HBV infected patients.Genet Mol Biol. 2019 Apr-Jun;42(2):337-343. doi: 10.1590/1678-4685-GMB-2018-0071. Epub 2019 Aug 19.
66 Altered mRNA levels of MOV10, A3G, and IFN- in patients with chronic hepatitis B.J Microbiol. 2014 Jun;52(6):510-4. doi: 10.1007/s12275-014-3467-8. Epub 2014 May 29.
67 Extraction and purification of hepatitis B virus-like M particles from a recombinant Saccharomyces cerevisiae strain using alumina powder.J Virol Methods. 2013 Jan;187(1):132-7. doi: 10.1016/j.jviromet.2012.09.023. Epub 2012 Oct 8.
68 Genetic variation in FCER1A predicts peginterferon alfa-2a-induced hepatitis B surface antigen clearance in East Asian patients with chronic hepatitis B.J Viral Hepat. 2019 Sep;26(9):1040-1049. doi: 10.1111/jvh.13107. Epub 2019 Jul 23.
69 N-myc and STAT interactor correlates with severity and prognosis in acute-on-chronic liver failure of hepatitis B virus.J Gastroenterol Hepatol. 2019 Oct;34(10):1800-1808. doi: 10.1111/jgh.14634. Epub 2019 Mar 7.
70 Peginterferon alfa-2a (40 kD) stopping rules in chronic hepatitis B: a systematic review and meta-analysis of individual participant data.Antivir Ther. 2019;24(2):133-140. doi: 10.3851/IMP3304.
71 Evaluation of serum procollagen C-proteinase enhancer 1 level as a fibrosis marker in patients with chronic hepatitis B.Eur J Gastroenterol Hepatol. 2018 Aug;30(8):918-924. doi: 10.1097/MEG.0000000000001123.
72 Serum regucalcin is a useful indicator of liver injury severity in patients with hepatitis B virus-related liver diseases.Braz J Med Biol Res. 2019 Sep 30;52(10):e8845. doi: 10.1590/1414-431X20198845. eCollection 2019.
73 Association of VARS2-SFTA2 polymorphisms with the risk of chronic hepatitis B in a Korean population.Liver Int. 2015 Aug;35(8):1934-40. doi: 10.1111/liv.12740. Epub 2015 Jan 10.
74 Association of cytokine and cytokine receptor gene polymorphisms with the risk of chronic hepatitis B.Asian Pac J Allergy Immunol. 2013 Dec;31(4):277-85. doi: 10.12932/AP0284.31.4.2013.
75 Decreased Siglec-9 Expression on Natural Killer Cell Subset Associated With Persistent HBV Replication.Front Immunol. 2018 May 30;9:1124. doi: 10.3389/fimmu.2018.01124. eCollection 2018.
76 Genetic variation in STAT4 is associated with treatment response to pegylated interferon in patients with chronic hepatitis B.Asian Pac J Allergy Immunol. 2022 Mar;40(1):87-93. doi: 10.12932/AP-020419-0533.
77 TNIP1 Polymorphisms with the Risk of Hepatocellular Carcinoma Based on Chronic Hepatitis B Infection in Chinese Han Population.Biochem Genet. 2019 Feb;57(1):117-128. doi: 10.1007/s10528-018-9882-5. Epub 2018 Aug 2.
78 Genetic analysis of complement component 9 (C9) polymorphisms with clearance of hepatitis B virus infection.Dig Dis Sci. 2011 Sep;56(9):2735-41. doi: 10.1007/s10620-011-1657-3. Epub 2011 Mar 5.
79 Relationship between polymorphism of class II transactivator gene promoters and chronic hepatitis B.World J Gastroenterol. 2005 Feb 14;11(6):854-7. doi: 10.3748/wjg.v11.i6.854.
80 Stimulation of human lymphocyte proliferation and CD40 antigen expression by phosphorothioate oligonucleotides complementary to hepatitis B virus genome.J Viral Hepat. 1996 Jul;3(4):167-72. doi: 10.1111/j.1365-2893.1996.tb00091.x.
81 Association of NKG2D genetic polymorphism with susceptibility to chronic hepatitis B in a Han Chinese population.J Med Virol. 2010 Sep;82(9):1501-7. doi: 10.1002/jmv.21855.
82 Association of a variant in MIR 196A2 with susceptibility to hepatocellular carcinoma in male Chinese patients with chronic hepatitis B virus infection.Hum Immunol. 2010 Jun;71(6):621-6. doi: 10.1016/j.humimm.2010.02.017. Epub 2010 Mar 12.
83 Involvement of REST corepressor 3 in prognosis of human hepatitis B.Acta Pharmacol Sin. 2011 Aug;32(8):1019-24. doi: 10.1038/aps.2011.49. Epub 2011 Jul 18.
84 Comparison of hepatic oxidative DNA damage in patients with chronic hepatitis B and C.J Viral Hepat. 2008 Jul;15(7):498-507. doi: 10.1111/j.1365-2893.2008.00972.x. Epub 2008 Mar 6.
85 A functional polymorphism in ADAR1 gene affects HBsAg seroclearance both spontaneously and interferon induced.Liver Int. 2014 Nov;34(10):1560-5. doi: 10.1111/liv.12444. Epub 2014 Jan 16.
86 Differential Activation of NLRP3, AIM2, and IFI16 Inflammasomes in Humans with Acute and Chronic Hepatitis B.Viral Immunol. 2018 Nov;31(9):639-645. doi: 10.1089/vim.2018.0058. Epub 2018 Sep 15.
87 RNA Interference Therapy With ARC-520 Results in Prolonged Hepatitis B Surface Antigen Response in Patients With Chronic Hepatitis B Infection.Hepatology. 2020 Jul;72(1):19-31. doi: 10.1002/hep.31008. Epub 2020 Apr 23.
88 Methylated cysteine dioxygenase-1 gene promoter in the serum is a potential biomarker for hepatitis B virus-related hepatocellular carcinoma.Tohoku J Exp Med. 2014 Mar;232(3):187-94. doi: 10.1620/tjem.232.187.
89 New liver cancer biomarkers: PI3K/AKT/mTOR pathway members and eukaryotic translation initiation factors.Eur J Cancer. 2017 Sep;83:56-70. doi: 10.1016/j.ejca.2017.06.003. Epub 2017 Jul 14.
90 A blood-based three-gene signature for the non-invasive detection of early human hepatocellular carcinoma.Eur J Cancer. 2014 Mar;50(5):928-36. doi: 10.1016/j.ejca.2013.11.026. Epub 2013 Dec 11.
91 Serum NOX2 as a new biomarker candidate for HBV-related disorders.Am J Transl Res. 2018 Aug 15;10(8):2350-2361. eCollection 2018.
92 Progression of Untreated Minimally Active Chronic HBV Infection Compared to Inactive Infection.Clin Gastroenterol Hepatol. 2019 Dec;17(13):2808-2810.e2. doi: 10.1016/j.cgh.2019.01.002. Epub 2019 Jan 11.
93 High promoter methylation levels of glutathione-S-transferase M3 predict poor prognosis of acute-on-chronic hepatitis B liver failure.Hepatol Res. 2017 May;47(6):566-573. doi: 10.1111/hepr.12777. Epub 2016 Aug 15.
94 HLA-C and KIR combined genotype as new response marker for HBeAg-positive chronic hepatitis B patients treated with interferon-based combination therapy.J Viral Hepat. 2016 Aug;23(8):652-9. doi: 10.1111/jvh.12525. Epub 2016 Mar 4.
95 Association between chronic hepatitis B virus infection and HLA-DP gene polymorphisms in the Turkish population.Virus Res. 2017 Mar 15;232:6-12. doi: 10.1016/j.virusres.2017.01.017. Epub 2017 Jan 22.
96 Genetic variants of heat shock protein A1L2437 and A1B1267 as possible risk factors for hepatocellular carcinoma in India.J Viral Hepat. 2013 Apr;20(4):e141-7. doi: 10.1111/jvh.12021. Epub 2012 Nov 20.
97 An association study of functional polymorphic genes IRF-1, IFNGR-1, and IFN- with disease progression, aspartate aminotransferase, alanine aminotransferase, and viral load in chronic hepatitis B and C.Int J Infect Dis. 2013 Jan;17(1):e44-9. doi: 10.1016/j.ijid.2012.08.004. Epub 2012 Oct 3.
98 The frequency and skewed T-cell receptor beta-chain variable patterns of peripheral CD4(+)CD25(+) regulatory T-cells are associated with hepatitis B e antigen seroconversion of chronic hepatitis B patients during antiviral treatment.Cell Mol Immunol. 2016 Sep;13(5):678-87. doi: 10.1038/cmi.2015.100. Epub 2016 Feb 22.
99 Serum Mac-2-Binding Protein Glycosylation Isomer at Virological Remission Predicts Hepatocellular Carcinoma and Death in Chronic Hepatitis B-Related Cirrhosis.J Infect Dis. 2020 Feb 3;221(4):589-597. doi: 10.1093/infdis/jiz496.
100 Memory Regulatory T cells Increase Only In Inflammatory Phase of Chronic Hepatitis B Infection and Related to Galectin-9/Tim-3 interaction.Sci Rep. 2017 Nov 10;7(1):15280. doi: 10.1038/s41598-017-15527-x.
101 Association of human leukocyte antigen DQB1 and DRB1 alleles with chronic hepatitis B.World J Gastroenterol. 2014 Jul 7;20(25):8179-86. doi: 10.3748/wjg.v20.i25.8179.
102 TIPE2 as a potential therapeutic target in chronic viral hepatitis.Expert Opin Ther Targets. 2019 Jun;23(6):485-493. doi: 10.1080/14728222.2019.1608948. Epub 2019 Apr 22.